ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Mar 09, 2023 09:07 JST
Source:
Eisai
Eisai Certified as a 2023 Health and Productivity Management Outstanding
TOKYO, Mar 09, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.
Under the Certified Health and Productivity Management Outstanding Organization Recognition Program, the Nippon Kenko Kaigi examines large enterprises, small and medium enterprises and other organizations engaging in initiatives for overcoming health-related challenges in regional communities or for promoting health-conscious activities led by the Nippon Kenko Kaigi. It recognizes outstanding enterprises engaging in efforts for health and productivity management by evaluating from a business-management perspective based on the following criteria: "management philosophy and policies", "organized frameworks", "systems and implementation of measures", and "evaluation and improvement". Eisai exceeded the average of its industry peers in all criteria, receiving particularly high scores for items such as "well adopted by employees" (in the criteria of organized frameworks), "lifestyle improvement" and "other measures*" (in the criteria of systems and implementation of measures). The program was launched in 2017, and this is the fifth time that Eisai was certified as a "White 500" company.
Eisai's corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Eisai calls this the "human health care (hhc)" concept. Eisai regards its employees as an important stakeholder and asset for the realization of its hhc concept. Eisai believes that its commitment to maintaining and improving the health of human resources is fundamental to develop highly engaged employees who are motivated to contribute voluntarily toward the realization of the hhc concept. Eisai issued the "Eisai Health Declaration" in 2019, and has strategically implemented health management for employees from a management perspective.
Eisai will continue to promote health and productivity management to increase non-financial value and further contribute to increasing the benefits of patients and the people in the daily living domain.
*Measures to address health issues specific to women and the elderly, long working hours, mental health, dependents of the company's employees, and prevention of infectious disease during COVID-19 pandemic.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Motors Premieres the All-New Colt for the European Market
Jun 09, 2023 20:28 JST
TOYOTA GAZOO Racing Unveils "GR H2 Racing Concept" at Le Mans 24 Hours
Jun 09, 2023 18:09 JST
Pilot Project for Lifelog-based Health Services in Muraoka-Fukasawa District
Jun 09, 2023 11:47 JST
Crafted Exclusively for the North American Market, Lexus Celebrates the World Premiere of the All-New TX
Jun 09, 2023 10:00 JST
World Premiere of the All-New Lexus GX
Jun 09, 2023 09:30 JST
Hitachi launches "Hitachi Application Reliability Centers Service" in Japan to enable cloud-native operations to drive both agility and reliability
Jun 08, 2023 16:50 JST
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
Jun 08, 2023 13:32 JST
MHI Inks MoU with TNB Genco on Clean Energy Technologies to Drive Decarbonization in Malaysia
Jun 07, 2023 15:56 JST
Aiming to Realize an Ever-Better Mobility Society, Toyota Mobility Foundation Selects 12 Teams for 2023 to Work on Activities in the "Mobility for ALL" Category of its Idea Contest
Jun 07, 2023 10:56 JST
JNTO, Mazda Motor Corporation, and TOYOTA GAZOO Racing Jointly Holding "Japan. Endless Discovery." Exhibit on Centenary of Le Mans 24 Hours Race
Jun 06, 2023 17:21 JST
NEC to supply East Micronesia Cable System (EMCS)
Jun 06, 2023 16:18 JST
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Jun 06, 2023 15:58 JST
Fujitsu 1FINITY Ultra Optical System selected by NTT for next Japan-wide core network
Jun 06, 2023 11:53 JST
Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision
Jun 05, 2023 16:00 JST
Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision
Jun 05, 2023 16:00 JST
Lexus Celebrates the World Premiere of the All-New LBX
Jun 05, 2023 15:35 JST
Mitsubishi Shipbuilding to Launch Technical Studies on Ammonia Fuel Supply System for Marine Engines under Development by WinGD
Jun 05, 2023 13:52 JST
Rovanpera increases lead with podium for TOYOTA GAZOO Racing
Jun 05, 2023 11:02 JST
JCB and Joint Stock Commercial Bank for Investment and Development of Vietnam launch the BIDV JCB Ultimate Credit Card in Vietnam
Jun 02, 2023 16:00 JST
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
Jun 02, 2023 12:20 JST
More Latest Release >>
Related Release
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
6/8/2023 1:32:00 PM JST
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
6/2/2023 12:20:00 PM JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
5/26/2023 2:15:00 PM JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
5/25/2023 9:02:00 PM JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
5/24/2023 6:03:00 PM JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
5/20/2023 10:20:00 AM JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
5/16/2023 9:27:00 AM JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
5/8/2023 11:15:00 AM JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
4/6/2023 6:32:00 PM JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
4/4/2023 1:23:00 PM JST
More Press release >>